Track record · closed signal

AstraZeneca PLC (AZN) — closed signal from August 13, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on November 11, 2025.

Predicted vs. what happened

AZN price · publication thesis → realized outcomesplit-adjusted
$77.15 Published $86.41 Target $89.09 Window close $89.32 Peak
$76.50 – $77.50Entry zone — fair-value band
$77.15Published — price the day we called it
$86.41Target — the price the thesis aimed for
$89.32Peak — highest point inside the window, not a realized return
$89.09Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 54 days.

Peak price
$89.32
peak on November 11, 2025 — not a realized return
Peak gain
+15.8%
peak, from the publication price
Window close
$89.09
end-of-window price, context only
Days to target
54
Window
August 13, 2025 – November 11, 2025

The thesis — published August 13, 2025

Predicted growth
+12%
over the measurement window
Target price
$86.41
the price the thesis aimed for
Entry zone
$76.50 – $77.50
the fair-value band we waited for
Price at publication
$77.15
published August 13, 2025
Confidence
70%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

AstraZeneca's price action looks healthy, with strong buying interest and a rising recent average price. News that it is widening access to an EGFR lung cancer treatment in Ghana, plus a respected industry award, both lift confidence in execution. The core numbers are mixed, but its steady healthcare profile supports cautious buys on small dips for a gradual climb over the next 0-3 months.

Primary drivers

  • Buying looks strong and the recent average price is trending upward
  • Wider access to EGFR lung cancer therapy in Ghana supports growth
  • Industry award boosts trust and draws more investor interest near term
  • Large, steady pharma name that can hold up in choppy markets

How it played out

AZN: target reached in 54 days

Lyra published AZN at $77.15 on 2025-08-13 with an expected gain of 12%. The thesis pointed to strong buying, a rising recent average price, wider access to an EGFR lung cancer therapy in Ghana, an industry award, and the steadier profile of a large pharma company.

Inside the window, AZN reached the $86.41 target in 54 days. It kept rising and peaked at $89.32 on 2025-11-11, with a 15.8% peak gain. It ended the window at $89.09. The thesis played out.

What happened during the window

On 2025-11-06, AstraZeneca reported third-quarter revenue of $15.2 billion, up 10%, and kept its full-year forecasts. On the same date, Investors.com reported that oncology sales rose to $6.64 billion in the September quarter.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All AZN signals